NC
ALLO icon

NinePointTwo Capital’s Allogene Therapeutics ALLO Stock Holding History

NinePointTwo Capital’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-50,402
Closed -$248K – 244
2023
Q1 		$248K Buy
50,402
+23,059
+84% +$148K 0.09% 137
2022
Q4 		$171K Buy
+27,343
New +$253K 0.07% 149

Other funds holding ALLO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

NinePointTwo Capital's ALLO Position: Q2 2023 in Review

NinePointTwo Capital sold out of Allogene Therapeutics (ALLO) in Q2 2023, closing a stake of 50,402 shares — an estimated $248K sold.

NinePointTwo Capital first reported a position in ALLO in Q4 2022 and held it in 2 quarters. The position peaked at $248K in Q1 2023. 171 funds tracked by Wall St. Rank hold ALLO as of Q2 2023.

  • NinePointTwo Capital reported no remaining Allogene Therapeutics position as of Q2 2023 after selling out during the quarter.
  • NinePointTwo Capital sold 50,402 Allogene Therapeutics shares in Q2 2023, an estimated $248K.
  • NinePointTwo Capital first reported a position in Allogene Therapeutics in Q4 2022 and held it in 2 quarters.
  • NinePointTwo Capital's Allogene Therapeutics position peaked at $248K in Q1 2023.
  • 171 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2023.

Based on NinePointTwo Capital's 13F filing for Q2 2023, filed 14 Aug 2023.